BELLEVILLE, ON, Jan. 7, 2014 /CNW/ - Bioniche Life Sciences Inc. (TSX:
BNC) (ASX: BNC), a leading clinical stage biotechnology company, today
announced the appointment of Donald Olds as Chief Operating Officer,
Dr. Michael Berendt, CEO of Bioniche Life Sciences Inc., highlighted
that, "the engagement of Donald Olds as Chief Operating Officer is the
next step in our operational plan to position Bioniche Life Sciences as
a top-tier North American biotechnology company with a focus on the
development of oncology therapeutics. Don brings a rare combination of
scientific, operational, and financial acumen that we are confident
will help us position our human therapeutic business for future success
and permit us to achieve our other operational objectives, including
the licensing and divestiture of our non-core business assets and the
implementation of operating cost reductions."
Prior to his new position with Bioniche Life Sciences, Mr. Olds has held
key executive positions in biotechnology, investment banking,
biotechnology and information technology where he has led successful
licensing, merger and acquisition and debt and equity transactions for
public and private companies.
He currently serves as Chairman of the Board, of the Neomed Institute (www.neomed.ca), is Director and Chair of the Audit Committee of the Centre Quebecois
(www.cqdm.org), is a Director of Bellus Health (TSX: BLU), and is Treasurer of Oxfam
Quebec (www.oxfam.qc.ca). Mr. Olds has a M.Sc. (University of British Columbia) and a MBA -
Finance & Strategy (McGill University).
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a clinical stage Canadian
biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary and innovative products for
the global human health market. The Company's primary goal is to
develop and commercialize products that advance human or animal health
and increase shareholder value.
For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly and
SOURCE: Bioniche Life Sciences Inc.
For further information:
Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058
Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097